JP2019501140A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501140A5
JP2019501140A5 JP2018527799A JP2018527799A JP2019501140A5 JP 2019501140 A5 JP2019501140 A5 JP 2019501140A5 JP 2018527799 A JP2018527799 A JP 2018527799A JP 2018527799 A JP2018527799 A JP 2018527799A JP 2019501140 A5 JP2019501140 A5 JP 2019501140A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
acceptable salt
compound
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018527799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501140A (ja
JP6882289B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/063485 external-priority patent/WO2017091661A1/en
Publication of JP2019501140A publication Critical patent/JP2019501140A/ja
Publication of JP2019501140A5 publication Critical patent/JP2019501140A5/ja
Priority to JP2021078741A priority Critical patent/JP7112567B2/ja
Application granted granted Critical
Publication of JP6882289B2 publication Critical patent/JP6882289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018527799A 2015-11-25 2016-11-23 二環式ｂｅｔブロモドメイン阻害剤及びその使用 Active JP6882289B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021078741A JP7112567B2 (ja) 2015-11-25 2021-05-06 二環式ｂｅｔブロモドメイン阻害剤及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259894P 2015-11-25 2015-11-25
US62/259,894 2015-11-25
PCT/US2016/063485 WO2017091661A1 (en) 2015-11-25 2016-11-23 Bicyclic bet bromodomain inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021078741A Division JP7112567B2 (ja) 2015-11-25 2021-05-06 二環式ｂｅｔブロモドメイン阻害剤及びその使用

Publications (3)

Publication Number Publication Date
JP2019501140A JP2019501140A (ja) 2019-01-17
JP2019501140A5 true JP2019501140A5 (enExample) 2020-01-09
JP6882289B2 JP6882289B2 (ja) 2021-06-02

Family

ID=57543210

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018527799A Active JP6882289B2 (ja) 2015-11-25 2016-11-23 二環式ｂｅｔブロモドメイン阻害剤及びその使用
JP2021078741A Active JP7112567B2 (ja) 2015-11-25 2021-05-06 二環式ｂｅｔブロモドメイン阻害剤及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021078741A Active JP7112567B2 (ja) 2015-11-25 2021-05-06 二環式ｂｅｔブロモドメイン阻害剤及びその使用

Country Status (8)

Country Link
US (2) US10508106B2 (enExample)
EP (2) EP3380469B1 (enExample)
JP (2) JP6882289B2 (enExample)
CN (2) CN115806550B (enExample)
AU (3) AU2016361441B2 (enExample)
CA (1) CA3006300C (enExample)
ES (2) ES2918589T3 (enExample)
WO (1) WO2017091661A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108314680A (zh) * 2017-01-16 2018-07-24 凯惠科技发展(上海)有限公司 一种含芳环化合物、其制备方法、药物组合物及应用
CN109111426B (zh) * 2017-06-23 2021-12-14 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物，及其用途
WO2019201296A1 (zh) * 2018-04-18 2019-10-24 南京明德新药研发有限公司 作为rho激酶抑制剂的吡唑类化合物
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
WO2020219168A1 (en) 2019-04-24 2020-10-29 Convergene, Llc Small molecule bromodomain inhibitors and uses thereof
KR102923602B1 (ko) * 2019-05-31 2026-02-06 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 피리도피리미딘 유도체
MA56022A (fr) 2019-05-31 2022-04-06 Chiesi Farm Spa Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
CA3196287A1 (en) * 2020-10-20 2022-04-28 Binhua Lv Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof
CN117279914A (zh) * 2021-01-29 2023-12-22 南京再明医药有限公司 Sos1抑制剂及其制备方法和应用
WO2022171018A1 (zh) * 2021-02-09 2022-08-18 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
EP4291195A4 (en) * 2021-02-11 2025-07-09 Medical College Wisconsin Inc SMALL MOLECULE INHIBITORS OF PBRM1-BD2
EP4317157A4 (en) * 2021-03-26 2025-04-09 Medshine Discovery Inc. 6-carbamate substituted heteroaryl ring derivatives
TW202416953A (zh) * 2022-08-26 2024-05-01 日商衛材R&D企管股份有限公司 抗體藥物複合物
WO2024235225A1 (zh) * 2023-05-15 2024-11-21 苏州泽璟生物制药股份有限公司 取代嘧啶并环类抑制剂及其制备方法和应用
WO2025209570A1 (zh) * 2024-04-03 2025-10-09 北京大学 Bet抑制剂及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
GB8908229D0 (en) * 1989-04-12 1989-05-24 Smithkline Beckman Intercredit Compounds
CA2114727C (en) * 1991-08-02 1996-12-10 Mikel P. Moyer Quinoline derivatives as immunostimulants
WO1999011658A1 (en) * 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. Meta-benzamidine derivatives as serin protease inhibitors
EP2048142A3 (en) * 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
SE0102858D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CA2557433C (en) * 2004-02-19 2013-05-14 Rexahn Corporation Quinazoline derivatives and therapeutic use thereof
AU2006216266C1 (en) * 2005-02-23 2010-08-26 Shionogi & Co., Ltd. Quinazoline derivative having tyrosine kinase inhibitory activity
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
US20090221624A1 (en) * 2005-05-06 2009-09-03 Olivo Paul D 4-aminoquinoline compounds for treating virus-related conditions
CA2700988A1 (en) * 2006-09-27 2008-05-08 Surface Logix, Inc. Rho kinase inhibitors
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
US20080200458A1 (en) * 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
GB0705915D0 (en) * 2007-03-28 2007-05-09 Helperby Therapeutics Ltd New use
US8003787B2 (en) * 2007-05-24 2011-08-23 Bayer Schering Pharma Ag Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors
AU2008321959B2 (en) * 2007-11-12 2014-02-13 Msd K.K. Heteroaryloxy quinazoline derivative
EP2072502A1 (de) * 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
WO2010056758A1 (en) * 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
US20110135655A1 (en) * 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
JP2013526484A (ja) * 2010-05-07 2013-06-24 グラクソ グループ リミテッド キナーゼ阻害剤としてのアミノ‐キノリン
US8933096B2 (en) * 2010-06-09 2015-01-13 Rugers, The State University of New Jersey Antimicrobial agents
EP2603502B1 (en) * 2010-08-13 2014-07-30 Janssen Pharmaceutica, N.V. 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors
WO2012040499A2 (en) * 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
CN103648500B (zh) * 2011-03-17 2016-05-04 宾夕法尼亚大学理事会 双功能酶制钳型分子的方法和用途
GB201106799D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
BR112013033417A2 (pt) * 2011-06-29 2016-08-16 Otsuka Pharma Co Ltd compostos terapêuticos e métodos relacionados de uso
WO2013086229A1 (en) * 2011-12-07 2013-06-13 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
US20130225611A1 (en) * 2011-12-09 2013-08-29 The Regents Of The University Of California Compositions and Methods for Reducing Cancer Cell Proliferation and Modulating Importin-Beta Function
US20130281397A1 (en) * 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US9201821B2 (en) * 2012-09-27 2015-12-01 Apple Inc. Interrupt timestamping
JP6457942B2 (ja) * 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
US9977024B2 (en) * 2012-12-09 2018-05-22 The Scripps Research Institute Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines
WO2014100501A1 (en) * 2012-12-20 2014-06-26 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
EA201591746A1 (ru) * 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
CN105473581B (zh) * 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
CA2919948C (en) * 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
WO2015112739A1 (en) * 2014-01-22 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for treating parp1-deficient cancers
JP6767875B2 (ja) * 2014-04-08 2020-10-14 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｔｇｆ−ベータ阻害剤としての２，３−二置換ピリジン化合物および使用方法
WO2015191568A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
WO2015200534A2 (en) * 2014-06-25 2015-12-30 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
US10106507B2 (en) * 2014-08-03 2018-10-23 H. Lee Moffitt Cancer Center and Research Insitute, Inc. Potent dual BRD4-kinase inhibitors as cancer therapeutics
WO2016120808A1 (en) * 2015-01-28 2016-08-04 Minoryx Therapeutics S.L. Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof
EP3072891A1 (en) * 2015-03-24 2016-09-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. New Toll-Like Receptor 9 Antagonists
CN108290855A (zh) * 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途

Similar Documents

Publication Publication Date Title
EP4356973A3 (en) 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
MX2023002688A (es) Compuestos farmaceuticos de arilo, heteroarilo, y heterociclicos para el tratamiento de trastornos medicos.
WO2020212895A1 (en) Method and apparatus to facilitate the binding of the gap protein to the mutant ras protein by molecular agents to cure ras-mutation related cancers
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
JP2009534455A5 (enExample)
TN2017000119A1 (en) Indole carboxamides compounds useful as kinase inhibitors
UA108369C2 (uk) Піролопіримідини як інгібітори cdk4/6
JOP20200114A1 (ar) عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون
CN110114083A (zh) 一种预防和治疗脂肪肝的方法
EA201800499A1 (ru) Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор
CN111902417A (zh) 一种二芳基巨环化合物、药物组合物以及其用途
CN113784963A (zh) 用作ret激酶抑制剂的化合物及其应用
JP2008523018A5 (enExample)
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
CN110891950A (zh) 一种三嗪化合物及其药学上可接受的盐
EP3666273A3 (en) Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
CN114072404A (zh) Ret选择性抑制剂及其制备方法和用途
CN113906026A (zh) 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
JP2019510075A5 (enExample)
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
DE602007004881D1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
CN109983015A (zh) 6-吡唑-[1,2,4]三唑并[4,3-a]吡啶-3-酰胺类衍生物、其制备方法及其在医药上的应用
UA88634C2 (en) Quaternized quinuclidine esters
CN109311893A (zh) 含有取代环戊基的吡咯并嘧啶化合物